{
    "nctId": "NCT00067314",
    "briefTitle": "Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy",
    "officialTitle": "A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 65,
    "primaryOutcomeMeasure": "To assess the anti-tumor activity of single-agent Edotecarin by determining the objective response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced or metastatic breast cancer not amenable to surgery or radiation with curative intent\n* Must have received any chemotherapy regimen in the past\n* Evidence of tumor resistance to last chemotherapy defined as progression after 6 months of previous chemotherapy for advanced disease\n* Must have measurable (by imaging techniques) disease\n* Adequate bone marrow, liver and renal function\n* Must provide evidence of informed consent and willingness and ability to comply with scheduled visits, treatment plan and study procedures.\n\nExclusion Criteria:\n\n* Received more than 2 prior chemotherapy regimens for metastatic disease\n* Received in the past another drug of the same class as the investigational drug, i.e. topoisomerase I inhibitor\n* Enrolled in another clinical intervention study\n* Pregnancy, breast feeding, fertile women refusing to use reliable contraceptive methods\n* Cardiac or thrombotic event in the last 12 months\n* Brain metastases",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}